What You’ll Learn in This Episode:

✔ What the JCA is and why it changes how we plan evidence generation

✔ When and how RWE can help answer comparator questions in HTA

✔ The risks of non-randomized comparisons—and how to mitigate them

✔ Why we need an integrated evidence plan early in development

✔ How tools like ROBINS-I and quantitative bias analysis can improve credibility

Why You Should Listen:

If you’re a statistician, medical affairs lead, or part of an HEOR or market access team, this episode will help you:

✔ Develop a stronger evidence generation plan across the drug lifecycle

✔ Understand how real world evidence can support JCA submissions

✔ Learn when RCTs aren’t enough—and how RWE can fill the gap

✔ Gain practical advice for designing indirect treatment comparisons

✔ Improve your bias assessment strategies with tools like ROBINS-I

Resources & Links:

🔗 ROBINS-I Tool – for evaluating bias in non-randomized studies

🔗 The Effective Statistician Academy – I offer free and premium resources to help you become a more effective statistician.

🔗 Medical Data Leaders Community – Join my network of statisticians and data leaders to enhance your influencing skills.

🔗 My New Book: How to Be an Effective Statistician - Volume 1 – It’s packed with insights to help statisticians, data scientists, and quantitative professionals excel as leaders, collaborators, and change-makers in healthcare and medicine.

🔗 PSI (Statistical Community in Healthcare) – Access webinars, training, and networking opportunities.

If you’re working on evidence generation plans or preparing for joint clinical advice, this episode is packed with insights you don’t want to miss.

Join the Conversation:
Did you find this episode helpful? Share it with your colleagues and let me know your thoughts! Connect with me on LinkedIn and be part of the discussion.

Subscribe & Stay Updated:
Never miss an episode! Subscribe to The Effective Statistician on your favorite podcast platform and continue growing your influence as a statistician.